Truist Financial Boosts Fresenius Medical Care (NYSE:FMS) Price Target to $25.00

Fresenius Medical Care (NYSE:FMS) had its price target lifted by Truist Financial from $23.00 to $25.00 in a research note published on Monday,Benzinga reports. Truist Financial currently has a hold rating on the stock.

A number of other analysts have also weighed in on the stock. StockNews.com initiated coverage on shares of Fresenius Medical Care in a report on Friday. They set a “strong-buy” rating for the company. Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price for the company. Finally, Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Fresenius Medical Care presently has an average rating of “Hold” and a consensus price target of $25.30.

Fresenius Medical Care Price Performance

Shares of NYSE:FMS opened at $22.79 on Monday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The firm has a market capitalization of $13.37 billion, a price-to-earnings ratio of 18.83, a PEG ratio of 0.95 and a beta of 0.94. The company’s fifty day moving average price is $22.28 and its 200-day moving average price is $20.69. Fresenius Medical Care has a one year low of $17.93 and a one year high of $24.31.

Institutional Trading of Fresenius Medical Care

A number of large investors have recently added to or reduced their stakes in the company. Allworth Financial LP raised its holdings in Fresenius Medical Care by 53.1% during the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after buying an additional 581 shares during the period. Mercer Global Advisors Inc. ADV grew its position in Fresenius Medical Care by 4.5% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company’s stock valued at $278,000 after acquiring an additional 624 shares during the last quarter. MML Investors Services LLC increased its stake in Fresenius Medical Care by 5.3% in the third quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock worth $320,000 after purchasing an additional 753 shares during the period. Rhumbline Advisers lifted its position in shares of Fresenius Medical Care by 6.7% during the second quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock worth $345,000 after purchasing an additional 1,128 shares during the last quarter. Finally, Marshall Wace LLP boosted its stake in shares of Fresenius Medical Care by 8.5% during the second quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock valued at $293,000 after purchasing an additional 1,207 shares during the period. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.